Sign In
Buy SLP
$16.17
-0.600 (-3.58%)
At Close: Jun 03, 2026
Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
San Diego, California--(Newsfile Corp. - June 3, 2026) - Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securi
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and dire
SLP Shareholder Alert: Robbins LLP Reminds Simulation Plus, Inc. Stockholders that it is Investigating the Company's Officers and Directors to
SAN DIEGO, June 2, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directo
SAN DIEGO--(BUSINESS WIRE)---- $SLP #AuditorDispute--Johnson Fistel, PLLP is investigating potential claims on behalf of Simulations Plus, Inc. (NASDAQ: SLP) investors concerning whether the Company o
SAN DIEGO--(BUSINESS WIRE)---- $SLP #Inc--Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directo
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws. T
Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
04:05pm, Thursday, 21'st May 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push
11:50am, Wednesday, 06'th May 2026
Simulations Plus, Inc. (NASDAQ:SLP) shares are trading lower on Wednesday as the company announced a collaboration with NVIDIA Corp (NASDAQ:NVDA), aimed at enhancing GPU-accelerated simulation and AI-
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
07:55am, Wednesday, 06'th May 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised
10:21am, Tuesday, 28'th Apr 2026
CDNS tops Q1 estimates, launches agentic AI Super Agents, hits a record $8B backlog, and raises its 2026 revenue outlook.
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of “Hold” from Brokerages
02:22am, Monday, 27'th Apr 2026
Simulations Plus, Inc. (NASDAQ: SLP - Get Free Report) has earned a consensus recommendation of "Hold" from the ten research firms that are currently covering the firm, MarketBeat.com reports. One equ
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
07:55am, Tuesday, 21'st Apr 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
07:55am, Monday, 20'th Apr 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
